2025-12-29 - Analysis Report
Okay, here's a breakdown of the Salesforce (CRM) stock analysis, based on the provided data, presented in a clear and organized manner.

**1) Return Rate Comparison**

*   **Company Overview:** Salesforce Inc. is a leading provider of cloud-based software for customer relationship management (CRM).
*   **CRM Cumulative Return:** -1.84%
*   **S&P 500 (VOO) Cumulative Return:** 103.21%
*   **Divergence:** -105.0 (Relative Divergence: 7.0)
    *   The significant negative divergence indicates a substantial underperformance of CRM compared to the broader market (S&P 500) over the specified period. The relative divergence suggests that the current divergence is near the bottom end of its historical range.

**Alpha, Beta Analysis**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 39.0% | 70.6% | 10.0% | -0.0 | 97.3 |
| 2016-2018  | 34.0% | 73.5% | 19.0% | 0.1 | 130.4 |
| 2017-2019  | 22.0% | 73.5% | 0.0% | 0.4 | 154.8 |
| 2018-2020  | 14.0% | 73.5% | -10.0% | 0.4 | 211.8 |
| 2019-2021  | 37.0% | 71.9% | -10.0% | 0.7 | 241.9 |
| 2020-2022  | -78.0% | 74.7% | -78.0% | 0.4 | 126.2 |
| 2021-2023  | -47.0% | 76.6% | -49.0% | -0.6 | 250.5 |
| 2022-2024  | -42.0% | 76.6% | -63.0% | -0.4 | 318.3 |
| 2023-2025  | 10.0% | 76.6% | -58.0% | -2.1 | 253.3 |

*   **CAGR:** Compound Annual Growth Rate. Shows the average annual growth rate over the period. Notice the significant drop in recent periods.
*   **MDD:** Maximum Drawdown. Represents the largest peak-to-trough decline during the period, indicating potential risk. MDD is consistently high.
*   **Alpha:** Measures the stock's performance relative to the benchmark (presumably the S&P 500).  Negative alpha values in recent periods suggest underperformance.
*   **Beta:** Measures the stock's volatility relative to the benchmark. Beta fluctuating shows varying correlation with the market.
*   **Cap(B):** Market Capitalization in Billions.

**Analysis:**

*   The data reveals a concerning trend. While Salesforce showed strong growth and positive alpha in earlier periods (2015-2019), recent periods (2020-2025) are characterized by negative CAGR, significantly negative alpha, and high maximum drawdowns. This indicates a period of significant underperformance and higher risk. The Beta shift to negative values, especially in the most recent period, suggests that CRM is moving in the opposite direction of the market and is less sensitive to market movements.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** 266.08
*   **Previous Close:** 265.26
*   **Change:** 0.31
*   **5-day SMA:** 263.86
*   **20-day SMA:** 255.75
*   **60-day SMA:** 248.01

**Analysis:**

*   The current price is above all three simple moving averages (SMAs), which *could* suggest short-term upward momentum.  However, the 5-day SMA is only slightly above the 20-day SMA, and the 20-day SMA is above the 60-day SMA, suggesting the upward momentum might be slowing down.  The recent change indicates a slight upward movement.

**3) Index Indicators**

*   **Market Risk Indicator (MRI):** 1.0 (High Investment Recommended)
*   **RSI:** 59.24 (Approaching overbought, but not there yet.)
*   **PPO:** 0.30 (Positive, indicating short-term momentum.)
*   **Hybrid Signal:**  "cash_0%_Buy 90% of cash (4 shares - Safe - MRI:0.80)"
*   **Recent (20 days) Relative Divergence Change:** -0.6 (Decreasing)
*   **Expected Return (%):** -639.9 (Extremely Negative)

**Analysis:**

*   The high MRI is contradictory to the other indicators. Typically, a high MRI suggests a favorable investment environment, but the exceptionally negative expected return strongly contradicts this.
*   The RSI suggests the stock is neither overbought nor oversold.
*   The PPO indicates positive short-term momentum, corroborating the recent price increase.
*   The hybrid signal leans towards a buy, but this should be interpreted with caution given the other conflicting indicators.
*   The decreasing relative divergence suggests that CRM's underperformance compared to the S&P 500 has worsened recently.
*   The *extremely negative* expected return is a major red flag. This suggests that, based on the current analysis, a long-term investment in CRM from this point is projected to significantly underperform the S&P 500.

**4) Recent News & Significant Events**

*   **Focus Areas:** AI, Analyst Ratings, Future Projections.
*   **Key Headlines:**
    *   "Salesforce Is Ready to Emerge an AI Winner. Buy the Stock." (Barron's) - Positive
    *   "Salesforce Just Triggered a Powerful Buy Signal for 2026" (MarketBeat) - Positive
    *   "Jim Cramer Says “Salesforce Now Has The Holy Grail”" (Yahoo Finance) - Positive
    *   "Could This Be Your Chance To Buy Salesforce Stock Cheaply?" (Forbes) - Positive
    *   "Salesforce Inc. (NYSE: CRM) Price Prediction and Forecast 2026-2030 (January 2026)" (24/7 Wall St.) - Neutral
    *   "Salesforce (CRM) Stock Today: Weekend Headlines, Analyst Price Targets, and What to Watch Before Monday’s Market Open" (ts2.tech) - Neutral
*   **Analysis:** The news sentiment is largely positive, focusing on potential future growth driven by AI and suggesting a potential buying opportunity.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (1.64 on a scale of 1-5)
*   **Opinions:** 53
*   **Target Price:** Average: 330.06, High: 475.00, Low: 223.00
*   **Recent Rating Changes:** (No changes listed)

**Analysis:**

*   Analysts, on average, have a "Buy" rating for CRM. The target price range is wide, indicating some uncertainty about the stock's future performance. The absence of recent rating changes suggests that analysts' views have been relatively stable recently.

**5) Recent Earnings Analysis**

| 날짜       | EPS   | 매출        |
|------------|-------|-------------|
| 2025-12-04 | 2.2   | 10.26 B$    |
| 2025-09-04 | 1.97  | 10.24 B$    |
| 2025-05-29 | 1.61  | 9.83 B$     |
| 2024-12-04 | 1.6   | 9.44 B$     |
| 2025-12-04 | 1.6   | 9.44 B$     |

**Analysis:**

*   Revenue and EPS have generally been increasing over the last few quarters. The most recent quarter (2025-12-04) shows a strong EPS of 2.2 and revenue of $10.26B. This indicates positive growth in earnings and sales.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-10-31   | $10.26B   | 78.02%        |
| 2025-07-31   | $10.24B   | 78.10%        |
| 2025-04-30   | $9.83B    | 76.96%        |
| 2025-01-31   | $9.99B    | 77.81%        |
| 2024-10-31   | $9.44B    | 77.71%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE     |
|--------------|-----------|---------|
| 2025-10-31   | $60.02B   | 3.48%   |
| 2025-07-31   | $61.33B   | 3.08%   |
| 2025-04-30   | $60.67B   | 2.54%   |
| 2025-01-31   | $61.17B   | 2.79%   |
| 2024-10-31   | $58.52B   | 2.61%   |

**Analysis:**

*   **Revenue and Profitability:** Revenue has been consistently growing, and profit margins are very high, suggesting good operational efficiency.
*   **Capital and Profitability:** Equity levels have remained relatively stable. ROE (Return on Equity) has fluctuated but shows an upward trend in the latest quarter.

**7) Comprehensive Analysis (Summary)**

*   **Performance:** CRM has significantly underperformed the S&P 500. Alpha Beta anlaysis also tells the same. The divergence highlights a concerning trend.
*   **Technical Indicators:** Mixed signals. While the short-term moving averages and PPO suggest some upward momentum, the RSI is neutral, and the change in relative divergence is negative. The extremely negative expected return is a major concern.
*   **News Sentiment:** Largely positive, emphasizing AI potential and possible buying opportunities.
*   **Analyst Opinions:** Positive overall, with a "Buy" consensus and a wide range of target prices.
*   **Earnings & Financials:** Recent earnings and revenue growth are positive signs, with high profit margins and increasing ROE.

**Overall Conclusion:**

The analysis presents a mixed picture. While recent earnings, financials, and analyst ratings paint a positive view of Salesforce's future, the significant underperformance relative to the market, the negative alpha, and the exceptionally negative expected return raise serious concerns. The high MRI is also contradictory to other indicators. Investors should carefully weigh these factors before making any investment decisions. The positive news sentiment and analyst outlook might be contributing to short-term positive price action, but the long-term outlook, based on the provided data, appears uncertain. The positive AI news need to be assessed to validate the future value.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.